T1	intervention 22 49	Palbociclib and Fulvestrant
T3	iv-cont-median 1897 1908	17.6 months
T4	cv-cont-median 1964 1974	8.8 months
T7	outcome 1519 1542	median overall survival
T8	iv-cont-median 1547 1558	39.7 months
T9	cv-cont-median 1623 1634	29.7 months
T12	total-participants 978 981	521
T13	outcome 1024 1047	median overall survival
T14	iv-cont-median 1052 1063	34.9 months
T15	cv-cont-median 1150 1161	28.0 months
T19	eligibility 440 582	patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had progression or relapse during previous endocrine therapy
T20	control 626 650	placebo plus fulvestrant
T21	intervention 594 622	palbociclib plus fulvestrant
T2	outcome 1850 1892	median time to the receipt of chemotherapy
T5	outcome 2321 2337	overall survival
T6	outcome 1773 1810	median duration of subsequent therapy
T10	outcome 2069 2082	afety signals
